Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation
Authors' conclusion
Semaglutide treatment may be associated with lower coronary artery inflammation in patients with T2DM, which might partially explain its cardiovascular protective mechanism.
Study context
- Population
- T2DM patients who underwent coronary CT angiography at Hebei General Hospital
- Participants
- 497 patients
- Exposure
- Semaglutide treatment vs no semaglutide
- Sema+n = 93
- Sema-n = 404reference
- Outcome
- Pericoronary fat attenuation index (FAI), a marker of coronary artery inflammation
Methodological detailspropensity-score matched, single-centre
- Propensity-score matched
- Single-centre
Main finding
As reported in the abstract
Pericoronary FAI after PSM
- Lower fat attenuation index (FAI) in all three major coronary arteries with Sema+ vs Sema- after propensity score matching (PSM)
- Multivariate linear regression: semaglutide independently associated with reduced FAI in all three major coronary arteries
- Propensity score matching
Observational data: associations, not effects.
Further findings
Pericoronary FAI before PSM
- FAI of the LAD and LCX lower with semaglutide vs without, before PSM
Subgroups
- Association varied across T2DM patients of differing profiles
Original publication
Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation. Cardiovasc Diabetol. Published 28 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →